Synopsis Refer to the Systematic Review for the 2017 ACC/ AHA/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death for the complete systematic evidence review for additional data and analyses.S7.9.1.3-15 The results from the question For asymptomatic patients with Brugada syndrome, what is the association be- tween an abnormal EP study and SCD and other ar- rhythmia endpoints? (Part 1) and the writing commit- tee s review of the totality of the literature were used to frame decision-making. Recommendations that are based on a body of evidence that includes the system- Figure 13. Exercise-induced polymorphic VT in catecholaminergic polymorphic ventricular tachycardia. Recommendations for Brugada Syndrome (Continued) COR LOE Recommendations CLINICAL STATEMENTS AND GUIDELINES atic review conducted by the ERC are denoted by the superscript SR (eg, LOE: B-RSR ). Factors identified as potential triggers of VF and SCA in Brugada syndrome include some psychotropic medica- tions, and anesthetic agents, cocaine, excessive alcohol intake, and fever (www.brugadadrugs.org).S7.9.1.3-21,S7.9.1.3-22 These agents should be avoided, and fever war- rants early and aggressive measures to reduce Recommendation-Specific Supportive Text 1. The risk of major adverse cardiac events in asymptomatic patients without spontaneous type 1 electrocardiographic changes of Brugada syndrome (Figure 15), or with only medica- tion-induced electrocardiographic changes, A positive family history of Brugada syndrome or SCA is not a signifi- cant predictor of adverse events in Brugada Implantation of an ICD in an asymptomatic patient without a spontaneous type 1 Brugada electrocardiographic has not been shown to confer any benefit. 2. Brugada syndrome is characterized by coved ST elevation in leads V1 or V2 positioned in the second, third, or fourth intercostal space either spontaneously or induced by administration of a sodium channel blocking drug in the absence Figure 14. 